Introduction

In a case that drew attention across the wearable technology and proximity-sensing sectors, ConnectQuest LLC v. Oura Health Oy concluded with a joint dismissal with prejudice on April 30, 2024 — just under 11 months after filing. The dispute, heard before Judge Xavier Rodriguez in the U.S. District Court for the Western District of Texas (Case No. 6:23-cv-00422), centered on two granted U.S. patents covering real-time data feeds in close proximity notification systems, technologies increasingly embedded in consumer wearables, health monitoring devices, and IoT ecosystems.

The outcome — a negotiated resolution resulting in dismissal of all claims — reflects a litigation landscape where proximity notification patent infringement assertions frequently drive early settlements, particularly when the accused products carry significant commercial value and market visibility. For patent practitioners, IP managers, and R&D teams operating in the wearable and connected-device space, this case offers instructive signals about assertion strategy, defensive posture, and the continuing commercial relevance of proximity notification patents.

Case Overview

The Parties

The Patents at Issue

Two U.S. patents formed the foundation of ConnectQuest’s infringement claims. Both patents fall within the technically and commercially active domain of proximity notification — a foundational layer for Bluetooth-enabled wearables, location-based services, and connected health devices.

• • U.S. Patent No. 9,681,264 B2 — Directed to systems and methods involving real-time data feeds within close proximity notification architectures.
• • U.S. Patent No. 9,219,990 B2 — Similarly addressing proximity-based notification systems with real-time data communication components.

Litigation Timeline & Procedural History

ConnectQuest filed suit on June 6, 2023, selecting the Western District of Texas — a venue that has historically attracted a disproportionate share of patent infringement filings due to its experienced patent docket, predictable scheduling orders, and plaintiff-favorable perception among NPE litigants.

The case proceeded at the district court (first instance) level under Chief Judge Xavier Rodriguez, a respected jurist with substantial experience managing complex commercial and intellectual property litigation on the Western District’s San Antonio docket.

The matter closed on April 30, 2024, after 329 days — a relatively efficient resolution for patent litigation, which nationally averages two to three years through trial. The compressed timeline strongly suggests that the parties engaged in productive settlement discussions well before any claim construction hearing or summary judgment briefing was completed, avoiding the most resource-intensive phases of patent litigation.

No publicly available record indicates that dispositive motions, Markman hearings, or expert reports reached adjudication before the parties filed their joint motion to dismiss.

The Verdict & Legal Analysis

Outcome

On April 30, 2024, Judge Rodriguez granted the parties’ Joint Motion to Dismiss pursuant to Federal Rule of Civil Procedure 41(a)(2). The Court ordered:

• • All claims asserted by ConnectQuest against Oura Health dismissed with prejudice
• • Each party to bear its own attorneys’ fees, costs of court, and expenses

No damages were publicly awarded, and no injunctive relief was issued. The specific terms of any underlying settlement agreement between the parties were not disclosed in the public record.

Verdict Cause Analysis

The case was initiated as a straightforward patent infringement action. The dismissal with prejudice — rather than without prejudice — is legally significant: it operates as a final adjudication on the merits, permanently barring ConnectQuest from re-asserting the same claims against Oura Health on the same patents. This structure is the standard hallmark of a negotiated resolution in which the defendant typically receives a license, covenant not to sue, or other agreed consideration in exchange for the plaintiff’s agreement to seek dismissal.

The mutual agreement that each party bear its own fees further suggests a balanced negotiated outcome, rather than a capitulation by either side. Had Oura Health successfully defeated the claims through litigation, it might have pursued fee-shifting under 35 U.S.C. § 285 in an “exceptional case” motion. The symmetric fee allocation signals a commercially pragmatic resolution rather than a legal victory for either party.

Legal Significance

While the case produced no published claim construction rulings or validity determinations, its significance lies in procedural and strategic patterns:

1. Venue Strategy: Western District of Texas remains a dominant NPE filing destination. Patent holders asserting proximity notification and IoT-adjacent patents continue to favor this jurisdiction for its efficient scheduling and experienced patent bench.
2. NPE Assertion Economics: The 329-day resolution window reflects the commercial calculus that frequently governs NPE disputes — assertion cost versus settlement cost. For a commercially successful defendant like Oura Health, resolving pre-claim construction may represent rational risk management.
3. Proximity Notification Patent Landscape: U.S. Patents 9,681,264 and 9,219,990 remain active and enforceable patents. Their assertion against a wearable health technology company signals that proximity notification IP portfolios are being actively deployed against consumer electronics and health-tech defendants — a trend R&D teams should monitor through regular freedom-to-operate (FTO) analyses.